UNLIMITED TURBO LONG - NOVO-NORDISK B | Real-time Borsa Italiana 08:34:25 2024-06-03 am EDT | ||
| 4.24 EUR | -4.29% |
|
| 1 month | +11.31% | ||
| 3 months | +41.08% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-03 | 4.24 | -4.29% |
| 24-05-31 | 4.43 | +3.26% |
| 24-05-30 | 4.29 | +0.70% |
| 24-05-29 | 4.26 | -1.39% |
| 24-05-28 | 4.32 | -0.92% |
Real-time Borsa Italiana
Last update June 03, 2024 at 08:34 am EDT
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| P1UKT8 | |
| ISIN | NLBNPIT1UKT8 |
| Date issued | 2023-09-22 |
| Strike | 621.2 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.63 € |
|---|---|
| Lowest since issue | 0.655 € |
| Spread | 0.01 € |
| Spread % | 0.24% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- P1UKT8 Certificat
